135 related articles for article (PubMed ID: 16236620)
1. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
Onitilo AA; Kio EA; Singh AK; Lazarchick J
Leuk Lymphoma; 2005 Nov; 46(11):1667-70. PubMed ID: 16236620
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
[No Abstract] [Full Text] [Related]
4. Imatinib-responsive hypereosinophilic syndrome.
Robyn J
Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
[No Abstract] [Full Text] [Related]
5. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
[TBL] [Abstract][Full Text] [Related]
7. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
Musto P; Perla G; Minervini MM; Carella AM; Coco FL; Catalano G
Leuk Res; 2004 Jul; 28(7):773-4. PubMed ID: 15158099
[No Abstract] [Full Text] [Related]
8. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
9. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate.
Sun CY; Hu Y; Chu ZB; Guo T; He J
Int J Hematol; 2009 Jan; 89(1):66-70. PubMed ID: 19096755
[TBL] [Abstract][Full Text] [Related]
11. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
[TBL] [Abstract][Full Text] [Related]
12. Images in cardiology: Hypereosinophilic syndrome and effect of imatinib mesylate.
Jacob S; Kovacs RJ
Clin Cardiol; 2005 Apr; 28(4):188. PubMed ID: 15869052
[No Abstract] [Full Text] [Related]
13. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
Wolf D; Gastl G; Rumpold H
Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
Cortes J; Ault P; Koller C; Thomas D; Ferrajoli A; Wierda W; Rios MB; Letvak L; Kaled ES; Kantarjian H
Blood; 2003 Jun; 101(12):4714-6. PubMed ID: 12595304
[TBL] [Abstract][Full Text] [Related]
15. Imatinib-responsive hypereosinophilia in a patient with B cell ALL.
Robyn J; Noel P; Wlodarska I; Choksi M; O'neal P; Arthur D; Dunbar C; Nutman T; Klion A
Leuk Lymphoma; 2004 Dec; 45(12):2497-501. PubMed ID: 15621767
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement.
Anghel G; De Rosa L; Ruscio C; Petti N; Riccardi M; Severino A; Majolino I
Tumori; 2005; 91(1):67-70. PubMed ID: 15850007
[TBL] [Abstract][Full Text] [Related]
17. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib.
Kobayashi M; Kubota T; Uemura Y; Taguchi H
Respirology; 2009 Mar; 14(2):302-4. PubMed ID: 19192229
[TBL] [Abstract][Full Text] [Related]
18. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
Pardanani A; Reeder T; Porrata LF; Li CY; Tazelaar HD; Baxter EJ; Witzig TE; Cross NC; Tefferi A
Blood; 2003 May; 101(9):3391-7. PubMed ID: 12506022
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
Tan D; Hwang W; Ng HJ; Goh YT; Tan P
Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
[TBL] [Abstract][Full Text] [Related]
20. Persistent cough: an unusual cause. Idiopathic hypereosinophilic syndrome (HES).
Barker B; Moudgil H; Slocombe G; Srinivasan K
Thorax; 2010 Nov; 65(11):1009, 1024. PubMed ID: 20965936
[No Abstract] [Full Text] [Related]
[Next] [New Search]